About: An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus
Creator	Baric, Ralph Schäfer, Alexandra Harcourt, Jennifer Tamin, Azaibi Sims, Amy Sheahan, Timothy Denison, Mark Agostini, Maria Bluemling, Gregory Brown, Chapell, James Dinnon Iii, Kenneth Graham, Rachel Hill, Kolykhalov, A Leist, Sarah Montgomery, Stephanie Natchus, Michael Painter, George Pruijssers, Andrea Saindane, Manohar Swanstrom, Ronald Thornburg, Zhou, Shuntai
Source	BioRxiv
abstract	Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2. Herein, we show that the ribonucleoside analog β-D-N4-hydroxycytidine (NHC, EIDD-1931) has broad spectrum antiviral activity against SARS-CoV 2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to another nucleoside analog inhibitor. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of EIDD-2801, an orally bioavailable NHC-prodrug (b-D-N4-hydroxycytidine-5’-isopropyl ester), improved pulmonary function, and reduced virus titer and body weight loss. Decreased MERS-CoV yields in vitro and in vivo were associated with increased transition mutation frequency in viral but not host cell RNA, supporting a mechanism of lethal mutagenesis. The potency of NHC/EIDD-2801 against multiple coronaviruses, its therapeutic efficacy, and oral bioavailability in vivo, all highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses.
has issue date	2020-03-20(xsd:dateTime)
bibo:doi	10.1101/2020.03.19.997890
has license	biorxiv
sha1sum (hex)	4a1213360996a18ae85d69618789e5daaa739e94
schema:url	https://doi.org/10.1101/2020.03.19.997890
resource representing a document's title	An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus
schema:publication	bioRxiv
resource representing a document's body	covid:4a1213360996a18ae85d69618789e5daaa739e94#body_text
is schema:about of	named entity 'disease' named entity 'species' named entity 'SARS-CoV-2' named entity 'guanine' named entity 'chain termination' named entity 'MHV' named entity 'viral RNA' named entity 'RNA' named entity 'ISG15' named entity 'reagent' named entity 'weight loss' named entity 'MERS-CoV' named entity 'ISG15' named entity 'mice' named entity 'IC50' named entity 'airway' named entity 'ISG15' named entity 'titer' named entity 'ISG15' named entity 'infection' named entity 'Phylogenetically' named entity 'dose-dependent manner' named entity 'weight loss' named entity 'cytotoxicity' named entity 'Bat' named entity 'lung' named entity 'MERS-CoV' named entity 'antiviral activity' named entity 'Uridine' named entity 'molecule' named entity 'cell cultures' named entity 'homogenate' named entity 'RdRp' named entity 'dose-dependent manner' named entity 'Molecular Devices' named entity 'prophylactic' named entity 'antibiotic' named entity 'pulmonary function' named entity 'mouse hepatitis virus' named entity 'human lung' named entity 'cytoxicity' named entity 'human disease' named entity 'titer' named entity 'lung hemorrhage' named entity 'mutation' named entity 'RNA' named entity 'SARS-CoV-2' named entity 'Uridine' named entity 'nonstructural protein' named entity 'plaque assay' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'lung' named entity '10.5' named entity 'transition mutation' named entity 'plasma' named entity 'prophylactic' named entity 'Adenine' named entity 'bronchoconstriction' named entity 'zoonotic' named entity 'highly conserved'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software